Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2010. The document serves as a notification to the U.S. Securities and Exchange Commission regarding a change in major shareholding interests, specifically an acquisition of voting rights by Legal & General Group plc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of share ownership changes and does not contain financial performance data.
Material Changes
The primary material change disclosed is the increase in Legal & General Group plc's (L&G) voting interest in GlaxoSmithKline plc. On August 3, 2010, L&G's holding crossed a regulatory threshold, increasing from 3% to 4% of total voting rights.
- Previous Holding: 207,179,146 shares (as of August 2, 2010).
- New Holding: 208,149,243 shares.
- Resulting Percentage: 4.00% of voting rights.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for management guidance, future outlook, specific risks, contingencies, or unusual items. The document is limited to the statutory notification of the share acquisition under DTR 5.8.12.
Investor Verification Points
- Verify the total number of voting rights outstanding (stated as 5,192,669,600) to confirm the 4.00% calculation.
- Confirm the breakdown of direct versus indirect holdings within the Legal & General Group structure.
- Check subsequent filings to determine if this 4% stake triggers further disclosure obligations or represents a strategic shift in ownership.